Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Equity Average (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Equity Average for 7 consecutive years, with $190.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 41.3% to $190.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $190.8 million, a 41.3% decrease, with the full-year FY2025 number at $242.6 million, down 37.6% from a year prior.
  • Equity Average was $190.8 million for Q4 2025 at Pliant Therapeutics, down from $210.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $547.5 million in Q2 2023 to a low of $160.8 million in Q2 2022.
  • A 5-year average of $318.0 million and a median of $277.1 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 487.98% in 2021, then tumbled 43.08% in 2025.
  • Pliant Therapeutics' Equity Average stood at $209.7 million in 2021, then skyrocketed by 55.03% to $325.2 million in 2022, then surged by 50.17% to $488.3 million in 2023, then plummeted by 33.45% to $325.0 million in 2024, then plummeted by 41.3% to $190.8 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Equity Average are $190.8 million (Q4 2025), $210.2 million (Q3 2025), and $238.6 million (Q2 2025).